TriangleAtezolizumab + Bevacizumab + SBRT (NCT05096715)
Atezolizumab + Bevacizumab + SBRT trial for Unresectable Hepatocellular Carcinoma (NCT05096715). This is a short film with English narration. The transcript is on this page, and the written brief is separate.
What the film says
Read the transcript
This trial is for adults with liver cancer, hepatocellular carcinoma, that cannot be removed with surgery.
The idea: combine standard atezolizumab and bevacizumab, two antibodies given by vein, with stereotactic body radiation therapy, a focused high dose of radiation aimed at the liver tumor.
The study looks at safety and how well patients tolerate it.
This phase 1 study plans 20 patients. At Massachusetts General Hospital in Boston, Jennifer Wo leads it.
Public record; not medical advice.
Already in a trial?
It turns into a project to manage: visits, scans, labs, side effects and paperwork. Triangle keeps it organized in one place for you or for whoever's helping.
Organize my trial7-day free trial, then $9 a month. Cancel anytime.
How these trials work: what Phase 1 actually is · common questions Not clinical evidence.